Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| RC-034-040-486 | 040-4861 | Peru | 2000 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | ATV+AZT+3TC | NA |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| I50L | L10V, K14R, M36I, A71AV, L89M |
| >040-4861| codons 1-99 PQITLWQRPVVTIRIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGLGGFIKVRQYD QILIEICGHKVIGTVLVGPTPVNIIGRNMLTQIGCTLNF |
References
| Author | Title | Citation |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |
| Colonno, RJ | Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. | J Infect Dis, 2004 |